Effect of subcutaneous semaglutide 2.4 mg once-weekly compared to placebo in subjects with obesity and knee osteoarthritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

30 Oct 2024 According to the Novo Nordisk Media Release, results from this study published in The New England Journal of Medicine.
30 Oct 2024 Primary endpoint (Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score) has been met, according to results present in the Novo Nordisk Media Release.
30 Oct 2024 Primary endpoint (Percentage Change in Body Weight) has been met, according to results present in the Novo Nordisk Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com